# NEOGENOMICS, INC. (NEO) FY2026 YTD Q2 P&L / Income Statement

- Company: NEOGENOMICS, INC. (NEO)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-28, accession number 0001077183-26-000059
- Page: https://plicit.ai/financials/neo/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/neo-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **NET REVENUE**: 388,328,000 US dollars
- **COST OF REVENUE**: 215,586,000 US dollars
- **GROSS PROFIT**: 172,742,000 US dollars
- **Total operating expenses**: 200,754,000 US dollars
- **LOSS FROM OPERATIONS**: negative 28,012,000 US dollars
- **Other income (expense), net (calculated)**: 12,260,000 US dollars
- **Income (loss) before taxes**: negative 15,752,000 US dollars
- **Income tax benefit**: negative 884,000 US dollars
- **Net income (loss)**: negative 14,868,000 US dollars
- **Client direct billing**: 269,545,000 US dollars
- **Commercial insurance**: 67,211,000 US dollars
- **Medicare and other government**: 51,572,000 US dollars
- **Self-pay**: 0 US dollars
- **General and administrative**: 129,354,000 US dollars
- **Research and development**: 20,295,000 US dollars
- **Sales and marketing**: 51,105,000 US dollars
- **Impairment charges (Note 5)**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.